Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that develops an immune medicine platform for diagnosing and treating various diseases. The company's core offering is its immunosequencing platform, which uses proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data that decodes the adaptive immune system. Its primary diagnostic product is clonoSEQ, a test that detects and monitors minimal residual disease (MRD) in cancer patients by measuring remaining cancer cells during and after treatment. This capability is particularly valuable in hematology-oncology, where it helps optimize patient care and drug development across lymphoid cancers. The company also develops solutions in cellular therapy and vaccines. Headquartered in Seattle, Washington, Adaptive Biotechnologies serves clinical laboratories, pharmaceutical companies, and healthcare providers seeking to leverage immune system insights for improved patient outcomes and precision medicine applications.